United Therapeutics achieves 12th consecutive quarter of growth, fueled by Tyvaso success. Discover insights on upcoming catalysts & $1B share buyback.

United Therapeutics ( NASDAQ: UTHR) has entered into two accelerated share repurchase deal to buy back an aggregate of $1 billion of its common stock. The company will repurchase these shares as part ...

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be announcing earnings results this Wednesday before market hours. Here’s what investors should know.

Biotechnology company United Therapeutics (NASDAQ:UTHR) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 11.7% year on year to $798.6 million. Its GAAP profit of $6.41 per ...

United Therapeutics Corp. ((UTHR)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools ...

United Therapeutics UTHR is set to give its latest quarterly earnings report on Wednesday, 2025-07-30. Here's what investors need to know before the announcement. Analysts estimate that United ...

United Therapeutics will repurchase these shares under the $1 billion repurchase program authorized by the company’s board of directors and previously announced on July 30, 2025.

United Therapeutics (UTHR) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus ...

United Therapeutics Corp. ((UTHR)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools ...

United Therapeutics Corp (NASDAQ:UTHR) reported second-quarter financial results before the market open on Wednesday. Here's a rundown of the report.